Chargement en cours...
Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?
The high molecular heterogeneity of bladder tumours is responsible for significant variations in disease course, as well as elevated recurrence and progression rates, thereby hampering the introduction of more effective targeted therapeutics. The implementation of precision oncology settings support...
Enregistré dans:
| Publié dans: | Oncotarget |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Impact Journals LLC
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5710962/ https://ncbi.nlm.nih.gov/pubmed/29207682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19433 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|